-
公开(公告)号:US20240400575A1
公开(公告)日:2024-12-05
申请号:US18798430
申请日:2024-08-08
Applicant: Universitat De Barcelona
Inventor: Sandra Codony Gisbert , Carlos Galdeano Cantador , Rosana Leiva Martínez , Andreea Larisa Turcu , Elena Valverde Murillo , Santiago Vázquez Cruz
IPC: C07D493/08 , C07C271/56 , C07C275/26 , C07C335/14 , C07D211/26 , C07D211/32 , C07D211/60 , C07D277/64 , C07D313/00
Abstract: The present invention relates to soluble epoxide hydrolase (sEH) inhibitors of formula (1) to processes for their obtention and to their therapeutic indications.
-
公开(公告)号:US20240279177A1
公开(公告)日:2024-08-22
申请号:US18392472
申请日:2023-12-21
Applicant: JIANGSU LIANHUAN PHARMACEUTICAL CO., LTD. , SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES
Inventor: Hong LIU , Ben NIU , Chunpu LI , Jianping CHEN , Kun HUANG , Jiang WANG
IPC: C07D211/60 , C07D401/12 , C07D409/12
CPC classification number: C07D211/60 , C07D401/12 , C07D409/12
Abstract: The present invention relates to the fields of medicinal chemistry and pharmaco therapeutics, and specifically to a method for preparing a compound of formula I and a chemically acceptable salt thereof.
-
公开(公告)号:US20240092788A1
公开(公告)日:2024-03-21
申请号:US18461886
申请日:2023-09-06
Applicant: Omeros Corporation
Inventor: Neil S. Cutshall , Jennifer Lynn Gage , Sara Rebecca Goldstein , Santosh Kumar Keshipeddy , Do Yeon Kwon , Robert Huerta Lemus , Thomas L. Little , Markus Metz , Jeremiah H. Nguyen , Peter Kurt Nollert Von Specht , Loren Michael Price , Jennifer Tsoung , Sudheer Babu Vaddela
IPC: C07D487/04 , C07D207/16 , C07D211/60 , C07D401/06 , C07D401/10 , C07D401/12 , C07D401/14 , C07D403/12 , C07D409/04 , C07D409/14 , C07D413/12 , C07D413/14 , C07D417/12 , C07D495/04 , C07F9/6558 , C07F9/6561 , C07D471/04
CPC classification number: C07D487/04 , C07D207/16 , C07D211/60 , C07D401/06 , C07D401/10 , C07D401/12 , C07D401/14 , C07D403/12 , C07D409/04 , C07D409/14 , C07D413/12 , C07D413/14 , C07D417/12 , C07D495/04 , C07F9/65583 , C07F9/6561 , C07D471/04
Abstract: The present disclosure provides, inter alia, compounds with MASP-2 inhibitory activity, compositions of such compounds, and methods of making and using such compounds.
-
公开(公告)号:US11897843B2
公开(公告)日:2024-02-13
申请号:US17941959
申请日:2022-09-09
Applicant: REUTER CHEMISCHE APPARATEBAU KG
Inventor: Karl Reuter , Tobias Wedel , Viktor Meier , Mark Kantor , Vasyl Andrushko , Florian Stolz
IPC: C07D211/56 , C07D211/60
CPC classification number: C07D211/56 , C07D211/60
Abstract: The present invention relates to a process for the preparation of enantiomerically enriched 3-aminopiperidine, as in particular of its R-enantiomer (R)-3-aminopiperidine. The invention also relates to an enantiomerically enriched intermediate of said process and to specific acid-addition salts of 3-aminopiperidine (hereinafter also APIP) that are useful for obtaining a single enantiomer of APIP, and to crystalline (R)-3-aminopiperidine-dihydrochloride-monohydrate and crystalline (S)-3-aminopiperidine-dihydrochloride-monohydrate.
-
公开(公告)号:US20240043439A1
公开(公告)日:2024-02-08
申请号:US18020242
申请日:2021-08-06
Applicant: Kira Pharmaceuticals (Suzhou) Ltd.
Inventor: Gonghua PAN , Xihua ZHU , Yingjie ZHU
IPC: C07D495/04 , C07D401/04 , C07D471/04 , C07D211/96 , C07D401/12 , C07D413/12 , C07D211/60 , C07D405/12 , C07D405/04 , C07D405/14 , C07D417/14 , C07D401/06 , C07D401/14 , C07F9/576 , C07D405/06 , C07D411/06 , C07D491/048 , C07D519/00 , C07D265/30 , A61P37/02 , C07F9/6561
CPC classification number: C07D495/04 , C07D401/04 , C07D471/04 , C07D211/96 , C07D401/12 , C07D413/12 , C07D211/60 , C07D405/12 , C07D405/04 , C07D405/14 , C07D417/14 , C07D401/06 , C07D401/14 , C07F9/5765 , C07D405/06 , C07D411/06 , C07D491/048 , C07D519/00 , C07D265/30 , A61P37/02 , C07F9/6561
Abstract: Disclosed generally relates to C5a receptor inhibitors, compositions thereof, methods of use thereof, and methods of preparation thereof.
-
公开(公告)号:US11802132B2
公开(公告)日:2023-10-31
申请号:US16969772
申请日:2019-02-22
Applicant: DANA-FARBER CANCER INSTITUTE, INC.
Inventor: Jun Qi , Lei Wu , Kenneth C. Anderson , Yan Song , Paul Park , Dharminder Chauhan
IPC: C07D495/14 , C07D211/60 , A61P35/00
CPC classification number: C07D495/14 , A61P35/00 , C07D211/60
Abstract: Provided herein are bifunctional compounds that bind a target protein (e.g., a selected protein) and/or induce ubiquitination for degradation of the target protein. In particular, provided are compounds that bind a bromodomain or bromodomain-containing protein (e.g., BET proteins) or histone methyltransferases (HMTs, e.g., enhancer of zeste homolog 1 (EZH1), or FKBP12) and can promote its degradation by recruiting it to the ubiquitin receptor RPN13 (e.g., RA190), for proteasomal degradation. Also provided are pharmaceutical compositions comprising the bifunctional compounds, methods of treating and/or preventing diseases (e.g., proliferative diseases, cancers, benign neoplasms, pathological angiogenesis, inflammatory diseases, and autoimmune diseases) and musculoskeletal diseases, and methods of inducing the degradation of a target (e.g., a target protein) by recruiting it to the ubiquitin receptor RPN13 of the proteasome in a subject by administering a compound or composition described herein.
-
公开(公告)号:US20230339851A1
公开(公告)日:2023-10-26
申请号:US18186265
申请日:2023-03-20
Applicant: CHEMOCENTRYX, INC.
Inventor: Hiufung CHU , Pingchen FAN , Yandong LI , Viengkham MALATHONG , Jay POWERS , Hiroko TANAKA , Yibin ZENG , Penglie ZHANG
IPC: C07D231/14 , C07D261/18 , C07D317/60 , C07D237/24 , C07D309/10 , C07D275/03 , C07D319/12 , C07D307/24 , C07D207/16 , C07D309/06 , C07D493/08 , C07D295/195 , C07D239/28 , C07D307/16 , C07D265/30 , C07D309/28 , C07D309/08 , C07D211/60 , C07D207/22 , C07D233/90 , C07D317/66 , C07D211/62 , C07D335/02 , C07C311/44 , C07D307/68 , C07D213/81 , C07D471/08
CPC classification number: C07C311/44 , C07D207/16 , C07D207/22 , C07D211/60 , C07D211/62 , C07D213/81 , C07D231/14 , C07D233/90 , C07D237/24 , C07D239/28 , C07D261/18 , C07D265/30 , C07D275/03 , C07D295/195 , C07D307/16 , C07D307/24 , C07D307/68 , C07D309/06 , C07D309/08 , C07D309/10 , C07D309/28 , C07D317/60 , C07D317/66 , C07D319/12 , C07D335/02 , C07D471/08 , C07D493/08 , C07C2601/02 , C07C2601/04 , C07C2601/08 , C07C2601/14 , C07C2601/16 , C07C2601/18 , C07C2602/08 , C07C2602/18 , C07C2602/42
Abstract: Provided are sulfonamide compounds having formula (I):
or a pharmaceutically acceptable salt thereof, wherein R, R1, R2, R3, R4 and the subscripts n and m have the meanings provided in the specification. The compounds are useful for treating diseases and conditions associated with CXCR6 activity.-
公开(公告)号:US20230331675A1
公开(公告)日:2023-10-19
申请号:US18042599
申请日:2021-09-08
Inventor: Yuguang WANG , Nong ZHANG , Tianzhi WU , Min HE , Xinliang WU , Shunli ZHANG
IPC: C07D211/60 , C07D265/30 , C07D241/04 , C07C229/18 , A61K45/06 , C07D401/12
CPC classification number: C07D211/60 , C07D265/30 , C07D241/04 , C07C229/18 , A61K45/06 , C07D401/12 , C07B2200/05
Abstract: An aromatic vinyl compound and preparation method therefor, and intermediate, pharmaceutical composition, and application thereof. The aromatic vinyl compound is represented by formula I-0. The aromatic vinyl compound has a significant inhibitory effect on PD-1/PD-L1, has a higher drug peak concentration, a larger area under the drug concentration time curve, better oral bioavailability, is a type of extremely effective small molecule inhibitor for PD-1/PD-L1, and can effectively alleviate or treat cancer and a related disease.
-
公开(公告)号:US11697639B2
公开(公告)日:2023-07-11
申请号:US16969005
申请日:2019-01-31
Applicant: WEST CHINA HOSPITAL, SICHUAN UNIVERSITY
Inventor: Jin Liu , Bowen Ke , Wensheng Zhang , Jun Yang , Lei Tang
IPC: C07D207/02 , C07D211/60 , C07C231/12 , C07C237/04 , C07D205/04 , C07D207/16 , C07D223/06 , C07D225/02
CPC classification number: C07D211/60 , C07C231/12 , C07C237/04 , C07D205/04 , C07D207/16 , C07D223/06 , C07D225/02
Abstract: A compound is shown in formula I and can be in the form of a pharmaceutically acceptable salt, or a stereoisomer, or a solvate, or a prodrug, or a metabolite. The compound takes effect rapidly and has a long-time local anesthetic effect following a single dose, with the sensory nerve blocking time being greater than the motor nerve blocking time, has both a long-acting local anesthetic effect and a selective local anesthetic effect, significantly reduces side effects of the compositions QX314 and QX314 and a quaternary ammonium salt compound with surfactant structural characteristics, and is safer. The compound of formula I of the present invention and a pharmaceutically acceptable salt thereof can be used for preparing drugs that have a long-time local anesthetic effect and a selective local anesthetic effect.
-
公开(公告)号:US11634443B2
公开(公告)日:2023-04-25
申请号:US17001123
申请日:2020-08-24
Applicant: United Therapeutics Corporation
Inventor: Kenneth Robert Phares , Hitesh Batra , Liang Guo
IPC: C07F9/6574 , C07C59/72 , C07D207/16 , C07D211/60 , C07D265/30 , C07D317/40 , C07D321/12 , C07F9/09 , A61K9/00 , A61K45/06
Abstract: Provided are novel prodrugs of treprostinil, as well as methods of making and methods of using these prodrugs.
-
-
-
-
-
-
-
-
-